Lidocaine hydrochlorideLidocaine hydrochloride
MedChemExpress (MCE)
HY-B0185A
73-78-9
Lignocaine hydrochloride
99.96%
4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture and light)
Room temperature in continental US
may vary elsewhere.
Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor.
Lidocaine hydrochloride (Lignocaine hydrochloride) (10 nM
48 hours) decreases significantly cell proliferation[2]. Lidocaine hydrochloride (1-10 nM
24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2]. Lidocaine hydrochloride (10 nM
48 hours) increases significantly the apoptotic cell rate[2]. Lidocaine hydrochloride (10 nM
48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2].
Lidocaine hydrochloride (Lignocaine hydrochloride) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block[3].
MEK ERK NF-κB
| | | |
| | | | | |
[1]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1
582(Pt 1):11. [Content Brief]
[2]. Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15
19(1):233. [Content Brief]
[3]. Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul
113(1):31-6. [Content Brief]